share_log
Reuters ·  Nov 8 05:05

Nov 07 (Reuters) - Ventyx Biosciences Q3 Operating Expenses USD 38.552 Million.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment